For targeted abdominal or visceral fat support, Tesamorelin has evidence in HIV-associated lipodystrophy, but it is not FDA-approved as a general weight-loss drug
There have been concerns related to counterfeit medications and varying quality among compounding pharmacies.[10,11] As supply shortages improve, there are also ongoing questions about the legality of continuing to compound certain medications.[12] For this reason, it is important to carefully research any pharmacy or provider offering compounded medications
Study 6 was a 68-week trial that enrolled 401 East-Asian patients (Japan and South Korea) with BMI greater than or equal to 35 kg/m2 and at least one weight-related comorbid condition or with BMI 27 to 34.9 kg/m2 and at least two weight-related comorbid conditions
[31] In February 2018, authorization was granted in the European Union, [16] [84] in March 2018 in Japan, [32] and in August 2019 in Australia
Worksite-based intensive lifestyle therapy has profound cardiometabolic benefits in people with obesity and type 2 diabetes
A Simpler Way to Access GLP-1 Care Body Forward offers a telehealth-based program designed for real life work with licensed providers without leaving home
